BRIEF—Grupo Biotoscana inks $30 million acquisition of Argentinian firm DOSA

Uruguay’s Grupo Biotoscana (GBT) has acquired Laboratorio DOSA, a specialty pharmaceutical manufacturer based in Argentina, for around $30 million.

DOSA, which has an annual revenue of about $18.5 million, produces products that treat severe pulmonary pathologies.

GBT chief executive Mariano García­Valiño said: "Today's announcement is an important milestone for us, as GBT continues to advance its strategic agenda and consolidates its position as the first pan-Latin American advanced medicines company."

"The acquisition will enhance GBT's product portfolio, add further in-house R&D and manufacturing capabilities, strengthen our product renewal pipeline and provide us with a new platform for growth and geographic expansion."